Bipolar Disorder
Bipolar disorder, characterised by extreme fluctuations in mood, is a complex mental health condition that affects approximately 45 million people worldwide. Current research on psychedelics as a potential treatment is limited due to concerns about inducing manic episodes, but emerging evidence, particularly regarding ketamine, suggests promise for alleviating depressive symptoms associated with the disorder.
What is Bipolar Disorder?
Bipolar disorder, previously known as manic-depressive illness, results in significant mood swings ranging from manic highs to depressive lows. The condition adversely affects energy, activity levels, concentration, and daily functioning capabilities.
There are three main classifications of bipolar disorder: bipolar I, characterised by prolonged manic episodes and depressive episodes of at least two weeks; bipolar II, involving patterns of depressive and hypomanic episodes without full-blown manic episodes; and cyclothymic disorder, which presents with periods of hypomanic and depressive symptoms lasting for at least two years.
Symptoms associated with manic episodes include decreased need for sleep, inflated self-esteem, and racing thoughts, while depressive states typically involve persistent sadness, loss of interest, feelings of worthlessness, and recurrent suicidal thoughts.
The aetiology of bipolar disorder remains uncertain, but genetic predisposition, notably having a first-degree relative with the disorder, is a significant risk factor. Diagnosis is often facilitated through structured clinical interviews and standardised assessment scales.
Current Treatments
First-line treatments for bipolar disorder typically encompass psychotherapy modalities such as cognitive behavioural therapy (CBT), interpersonal and social rhythm therapy (IPSRT), and family-focused therapy, often in conjunction with medication like mood stabilisers (e.g., lithium), antipsychotics, and antidepressants.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Bipolar Disorder.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ketamine Significant evidence supports ketamine's efficacy in reducing depressive symptoms in bipolar disorder. | Large | Moderate | Consistent |
| Psilocybin Ongoing clinical trials will provide more data on psilocybin's safety and efficacy in bipolar disorder contexts. | Medium | Low | Inconsistent |
| LSD Current scepticism about LSD's use stems from risks of manic episodes. | None | Very Low | Inconsistent |
Ketamine and Bipolar Disorder
Ketamine is a non-competitive antagonist of the NMDA receptor, generating rapid antidepressant effects that may help stabilize mood in individuals with bipolar disorder. Its unique pharmacological profile allows for the amelioration of depressive symptoms without the serotonergic pathways that traditional psychedelics affect, thereby reducing the risk of inducing mania during treatment.
Psilocybin and Bipolar Disorder
As a classic psychedelic, psilocybin primarily acts as a 5-HT2A agonist, which raises concerns about potential manic episode activation in bipolar patients. Nevertheless, research is cautiously exploring its viability in treating the depressive aspects of bipolar disorder, particularly when administered in controlled settings and during non-manic phases.
Key Insights
- 1
The intricate nature of bipolar disorder complicates treatment, necessitating a combination of psychotherapeutic and pharmacological approaches.
- 2
Research indicates a potential for ketamine to alleviate depressive symptoms in bipolar disorder, although its long-term efficacy remains uncertain.
- 3
Concerns about psychedelics inducing manic episodes have led researchers to approach this treatment area with caution, particularly concerning classic psychedelics like LSD and psilocybin.
- 4
Current clinical trials exploring psychedelics for bipolar disorder, particularly psilocybin, focus on individuals in depressive states, which may mitigate the risk of triggering mania.
- 5
A recognised need for further research into the safe application of psychedelic therapy in bipolar disorder is crucial, especially given the potential interactions with common medications such as lithium.
Industrial Landscape
Key stakeholders include academic institutions conducting clinical trials, notably the Sheppard Pratt Health System in collaboration with Compass Pathways, as well as various researchers exploring the implications of psychedelics in mood disorders.
Quick Indicators
\"Ongoing clinical evaluations are investigating Bipolar Disorder as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Bipolar Disorder.